MicroRNAs miR-27a and miR-143 Regulate Porcine Adipocyte Lipid Metabolism

Wang, Tao; Li, Mingzhou; Guan, Jiuqiang; Li, Penghao; Wang, Huiyu; Guo, Yanqin; Shuai, Surong; Li, Xuewei

doi:10.3390/ijms12117950

Cited by 72 publications

(67 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…miR-22 could repress fatty acid synthesis and was an important regulator of lipid and folate metabolism in breast cancer cells (Koufaris et al, 2016). miR-27a was reported to accelerate adipolysis releasing significantly more glycerol and free fatty acids (Wang et al, 2011). miR-155 could driver the metabolic reprogramming in ER + breast cancer cells (Bacci et al, 2016), and its overexpression could promote the aberrant expression of hepatic genes associated with lipid metabolism in a mice model of liver (Lin et al, 2015).…”

Section: Discussionmentioning

confidence: 99%

High Expression of CPT1A Predicts Adverse Outcomes: A Potential Therapeutic Target for Acute Myeloid Leukemia

Shi

Jia

et al. 2016

EBioMedicine

View full text Add to dashboard Cite

Carnitine palmitoyl transferase 1A (CPT1A) protein catalyzes the rate-limiting step of Fatty-acid oxidation (FAO) pathway, which can promote cell proliferation and suppress apoptosis. Targeting CPT1A has shown remarkable anti-leukemia activity. But, its prognostic value remains unclear in Acute Myeloid Leukemia (AML). In two independent cohorts of cytogenetically normal AML (CN-AML) patients, compared to low expression of CPT1A (CPT1Alow), high expression of CPT1A (CPT1Ahigh) was significantly associated with adverse outcomes, which was also shown in European Leukemia Network (ELN) Intermediate-I category. Multivariable analyses adjusting for known factors confirmed CPT1Ahigh as a high risk factor. Significant associations between CPT1Ahigh and adverse outcomes were further validated whether for all AML patients (OS: P = 0.008; EFS: P = 0.002, n = 334, no M3) or for National Comprehensive Cancer Network (NCCN) Intermediate-Risk subgroup (OS: P = 0.021, EFS: P = 0.024, n = 173). Multiple omics analysis revealed aberrant alterations of genomics and epigenetics were significantly associated with CPT1A expression, including up- and down-regulation of oncogenes and tumor suppressor, activation and inhibition of leukemic (AML, CML) and immune activation pathways, hypermethylation enrichments on CpG island and gene promoter regions. Combined with the previously reported anti-leukemia activity of CPT1A's inhibitor, our results proved CPT1A as a potential prognosticator and therapeutic target for AML.

show abstract

Section: Discussionmentioning

confidence: 99%

High Expression of CPT1A Predicts Adverse Outcomes: A Potential Therapeutic Target for Acute Myeloid Leukemia

Shi

Jia

et al. 2016

EBioMedicine

View full text Add to dashboard Cite

show abstract

“…miR-143 has been shown to accelerate adipogenesis and regulates lipid metabolism in both human and rodents [83, 88, 89]. Overexpression of miR-143 in preadipocytes increases the expression of adipocyte differentiation markers such as CCAAT/enhancer binding protein (C/EBP)-β, peroxisome proliferator activated receptor-γ (PPARγ), adipocyte fatty acid binding protein 4 (FABP4) and leptin [83, 87, 90].…”

Section: Mirnas In Regulating Insulin Sensitivity In Skeletal Muscmentioning

confidence: 99%

MicroRNAs as pharmacological targets in diabetes

Mao

Mohan

Zhang

et al. 2013

Pharmacological Research

View full text Add to dashboard Cite

Diabetes is characterized by high levels of blood glucose due to either the loss of insulin-producing beta-cells in the pancreas, leading to a deficiency of insulin in type 1 diabetes, or due to increased insulin resistance, leading to reduced insulin sensitivity and productivity in type 2 diabetes. There is an increasing need for new options to treat diabetes, especially type 2 diabetes at its early stages due to the ineffective control of its development in patients. Recently, a novel class of small noncoding RNAs, termed microRNAs (miRNAs), found to play a key role as important transcriptional and posttranscriptional inhibitors of gene expression in fine-tuning the target messenger RNAs (mRNAs). miRNAs are implicated in the pathogenesis of diabetes and have become an intriguing target for therapeutic intervention. This review focuses on the dysregulated miRNAs discovered in various diabetic models and addresses the potential for miRNAs to be therapeutic targets in the treatment of diabetes.

show abstract

“…Recent molecular-based approaches have expanded our knowledge of the impact of diet in regulating bovine adipogenesis by examining effects on mRNA (Dahlman et al, 2005;Joseph et al, 2010) or microRNA (miRNA) expression in various adipose depots (Romao et al, 2012). These studies suggest the molecular mechanisms regulating bovine adipogenesis differ from those of humans (Esau et al, 2004), mice (Esau et al, 2006;Krutzfeldt et al, 2005), and pigs (Wang et al, 2011), thus suggesting that although adipogenic miRNA are conserved across species, the molecular mechanisms underlying their regulation are highly species specific (Jin et al, 2010;Romao et al, 2012).…”

Section: Introductionmentioning

confidence: 99%

Effect of diet on microRNA expression in ovine subcutaneous and visceral adipose tissues1

Meale

Romao

et al. 2014

Journal of Animal Science

View full text Add to dashboard Cite

Knowledge of the molecular mechanisms that regulate ovine adipogenesis is very limited. MicroRNAs (miRNA) have been reported as one of the regulatory mechanisms of adipogenesis. This study aimed to compare the expression of miRNA related to ovine adipogenesis in different adipose depots and to investigate whether their expression is affected by dietary fatty acid composition. We also investigated the role of miRNA in adipogenic gene regulation. Subcutaneous and visceral adipose tissue samples were collected at slaughter from 12 Canadian Arcott lambs fed a barley-based finishing diet where an algae meal (DHA-Gold; Schizochytrium spp.) replaced flax oil and barley grain at 0 or 3% DM (n = 6). Total RNA from each tissue was subjected to quantitative real time (qRT-) PCR analysis to determine the expression of 15 selected miRNA including 11 identified from bovine adipose tissues and 4 conserved between bovine and ovine species. MicroRNAs were differentially expressed according to diet in each tissue depot (miR-142-5p and miR-376d) in visceral and miR-142-5p, miR92a, and miR-378 in subcutaneous adipose tissue; P ≤ 0.05) and in each tissue depot depending on diet (miR-101, miR-106, miR-136, miR-16b, miR-196a-1, miR-2368*, miR-2454, miR-296, miR-376d, miR-378, and miR-92a in both control and DHA-G diets and miR-478 in control; P ≤ 0.05). Six miRNA were subjected to functional analysis and 3 genes of interest (ACSL1, PPARα, and C/EBPα) were validated by qRT-PCR. Both diet and tissue depot affected expression levels of all 3 genes (P < 0.05). miR-101, miR-106, and miR-136 were negatively correlated with their respective predicted gene targets C/ EBPα, PPARα, and ACSL1 in subcutaneous adipose tissue of lambs fed DHA-G. Yet miR-142-5p and miR-101 showed no correlation with ACSL1 or C/EBPα. The variability in expression patterns of miRNA across adipose depots reflects the tissue specific nature of adipogenic regulation. Although the examined miRNA appear to be conserved across ruminant species, our results indicate the presence of ovine specific regulatory mechanisms that can be influenced by diet.

show abstract

MicroRNAs miR-27a and miR-143 Regulate Porcine Adipocyte Lipid Metabolism

Cited by 72 publications

References 19 publications

High Expression of CPT1A Predicts Adverse Outcomes: A Potential Therapeutic Target for Acute Myeloid Leukemia

High Expression of CPT1A Predicts Adverse Outcomes: A Potential Therapeutic Target for Acute Myeloid Leukemia

MicroRNAs as pharmacological targets in diabetes

Effect of diet on microRNA expression in ovine subcutaneous and visceral adipose tissues1

Contact Info

Product

Resources

About